Oncopeptides AB (OSTO:ONCO) Future 3-5Y EPS without NRI Growth Rate : N/A (As of May. 21, 2025)

View and export this data going back to 2017. Start your Free Trial

What is Oncopeptides AB Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Oncopeptides AB's Future 3-5Y EPS without NRI Growth Rate is N/A.

Competitive Comparison of Oncopeptides AB's Future 3-5Y EPS without NRI Growth Rate

For the Biotechnology subindustry, Oncopeptides AB's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncopeptides AB's Future 3-5Y EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncopeptides AB's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Oncopeptides AB's Future 3-5Y EPS without NRI Growth Rate falls into.

Save Embed

;

Save Embed

;

Oncopeptides AB (OSTO:ONCO) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Oncopeptides AB Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Oncopeptides AB's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncopeptides AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncopeptides AB (OSTO:ONCO) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

0RN4:UK OND:Germany

Address

Vastra Tradgardsgatan 15, Stockholm, SWE, SE-111 53

Website

https://www.oncopeptides.com

Oncopeptides AB is a biotech company focused on the research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Conjugate (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It has focused on the development of the product candidate Melflufen (Pepaxti), a peptide-conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment for hematological cancers and in particular multiple myeloma.